Highest-materiality recent filing
MaxCyte regains compliance with Nasdaq $1.00 bid price rule
Received Nasdaq notice on June 10, 2026 that closing bid price has been ≥$1.00 for 10 consecutive business days (May 27 – June 9, 2026).
MaxCyte Q1 revenue $9.7M (-7% YoY); net loss narrows to $4.8M; board authorizes $10M buyback
Core revenue $6.2M (-25% YoY); SPL-related revenue rose to $3.4M from $2.1M.
MaxCyte appoints Parmeet Ahuja as CFO effective March 30, 2026
Parmeet Ahuja succeeds Douglas Swirsky, who is transitioning from the role as announced in November 2025.
MaxCyte Q4 revenue $7.3M, down 16%; FY2025 revenue $33M; guides FY2026 $30-32M
Q4 2025 total revenue $7.3M (-16% YoY); Core revenue $6.8M (-22% YoY). Net loss $9.6M.
MaxCyte receives Nasdaq notice for bid price below $1.00; 180-day cure period
Closing bid price below $1.00 for 30 consecutive days as of March 16, 2026.
MaxCyte Q3 revenue down 16% YoY to $6.8M; reiterates FY2025 guidance
Total revenue $6.8M (-16% YoY); core revenue $6.4M (-21% YoY).
MaxCyte reports preliminary Q3 2025 revenue of $6.8M, down 16% YoY; reiterates FY2025 guidance
Total revenue $6.8M, core revenue $6.4M (-21% YoY); adds three new SPL clients including Moonlight Bio.
MaxCyte cuts ~34% of workforce, expects $13.6M annual savings; reiterates 2025 revenue outlook.
Workforce reduction of ~34% globally, including EOR arrangements; expects pre-tax cash charges of $2.9M.
MaxCyte Q2 revenue down 18% YoY; lowers 2025 core revenue guidance
Total revenue $8.5M, down 18% YoY; core revenue up 8% to $8.2M.
MaxCyte Q4 core revenue +20%, total rev -45% on milestone comp; FY2025 core growth 8-15%
Q4 2024 total revenue $8.7M (-45% YoY); core revenue ex-milestones $8.6M (+20%); net loss $10.6M vs $5.3M.
MaxCyte cuts 15% workforce, raises 2024 core revenue growth guidance to 6-8%
Reduction of 21 positions (~15% of global workforce) approved December 4, 2024.
MaxCyte Q3 core revenue up 23% YoY to $8.1M; net loss $11.6M; guidance raised
Total Q3 revenue $8.2M (+2% YoY); core business revenue $8.1M (+23% YoY) driven by cell therapy growth of 39%.
MaxCyte Q2 revenue up 15% to $10.4M; core revenue down 9% to $7.6M; SPL revenue jumps 279%
Total revenue $10.4M (+15% YoY); core business revenue $7.6M (-9% YoY); SPL program-related revenue $2.9M (+279% YoY).
MaxCyte Q1 revenue $11.3M (+32% YoY); updates 2024 SPL guidance to ~$5M
Total revenue $11.3M, up 32% YoY; core revenue $8.2M, up 5%.
MaxCyte Q4 revenue $15.7M (+26% YoY) but core down 32%; net loss $5.3M; reiterates 2024 guidance
Q4 total revenue $15.7M (+26% YoY); core business revenue $7.2M (-32%); SPL program-related $8.5M (+359%).
MaxCyte provides FY2024 guidance: core flat to +5%; FY2023 prelim core down 25% YoY
FY2023 prelim total revenue $41.1-$41.3M (vs $44.3M in 2022); core revenue $29.6-$29.8M (vs $39.6M), down ~25%.
MaxCyte reports prelim Q4 total revenue $15.5-15.7M, core down YoY; FY total revenue $41.1-41.3M
Q4 2023 total revenue expected $15.5-15.7M (Q4 2022: $12.4M); core revenue $7.0-7.2M (down from $10.6M) and SPL revenue ~$8.5M (up from $1.9M).
Doug Doerfler retires as President and CEO effective Dec 31, 2023; remains as advisor.
MaxCyte Q3 revenue down 25% to $8.0M, net loss widens; FY guidance reiterated
Total revenue $8.0M (-25% YoY); core business revenue $6.6M (-33%).
MaxCyte preliminary Q3 revenue $7.8-8.0M; cuts FY2023 revenue guidance to $34-36M
Q3 total revenue expected $7.8-8.0M, down 25-27% YoY; core revenue $6.4-6.6M, down 33-35% YoY.
MaxCyte Q2 revenue down 6% YoY, core revenue down 14%; expects 2023 core revenue flat to 2022
Total revenue $9.0M in Q2 2023 (-6% YoY); core business revenue $8.3M (-14% YoY).
MaxCyte Q1 revenue $8.6M (-26% YoY), net loss $10.9M; cuts FY23 revenue growth guidance to 8-12%
Total revenue $8.6M, down 26% YoY; core business revenue $7.8M, down 19%.
MaxCyte names Douglas Swirsky as CFO; salary $425K, option for 350K shares
Douglas J. Swirsky appointed CFO and principal accounting officer, effective March 27, 2023.
MaxCyte FY2022 total revenue $44.3M (+31% YoY); net loss $23.6M
Q4 2022 revenue $12.4M (+22% YoY); core revenue $10.6M (+4%); gross margin 88%.
MaxCyte reports preliminary FY2022 revenue $44.3M (+31% YoY); guides 2023 growth 21-26%
FY2022 total revenue ~$44.3M, up 31% from $33.9M in 2021; Q4 revenue ~$12.4M, up 22%.
MaxCyte Q3 revenue up 5% to $10.6M; core business grows 22%; net loss widens to $6.4M
Total revenue $10.6M (+5% YoY); core business revenue $9.9M grew 22% led by cell therapy +27%.
MaxCyte Q2 revenue $9.6M (+35% YoY); raises 2022 core revenue growth guidance to ~30%
Total revenue $9.6M (+35% YoY); core business revenue +45% led by cell therapy +61%.
MaxCyte Q1 revenue $11.6M (+78% YoY); raises 2022 core revenue guidance to at least 25%
Total revenue $11.6M, up 78% YoY; core business revenue $9.6M, up 48% YoY driven by cell therapy customers (+57%).
MaxCyte CFO resigns; appoints Ron Holtz as interim CFO; Q1 revenue at least $11M
Amanda Murphy resigns as CFO effective April 15, 2022; Ron Holtz (former CFO 2005-2020, CAO) named interim CFO.
MaxCyte Q4 revenue record $10.2M (+19%), FY2021 $33.9M (+30%); guides 2022 core growth 22-25%
Record Q4 revenue $10.2M (+19% YoY); FY revenue $33.9M (+30% YoY).
MaxCyte preliminary Q4 rev >$10M (+17% YoY); FY rev >$33.7M (+28%); adds 4 SPLs in 2021
Q4 2021 preliminary revenue >$10.0M (up from $8.5M in Q4 2020); core business revenue grew at least 37%.
MaxCyte Q3 revenue up 50% to $10.1M; raises FY2021 guidance to at least $33M
Total revenue $10.1M (+50% YoY); net loss ($2.7M) improved from ($3.1M) prior year.
MaxCyte Q2 revenue up 38% to $7.1M, net loss widens to $4.4M; guides FY2021 revenue ~$30M
Revenue $7.1M (+38% YoY); cell therapy ex-SPL $4.8M (+59%), drug discovery $1.8M (+60%).
On January 23, 2024, Cenk Sumen, Ph.D.’s employment as Chief Scientific Officer of MaxCyte, Inc. (the “ Company ”), ended.
On December 10, 2023, Doug Doerfler, President and Chief Executive Officer of MaxCyte, Inc. (the “ Company ”), notified the Company’s Board of Directors (the “ Board ”) of his decision to retire from those positions and as a member of the Board, in each case effective as of December 31, 2023 (the “ Retirement Date ”).
On December 10, 2023, the Board appointed Maher Masoud, currently the Company’s Executive Vice President, General Couns...
Ron Holtz, who had served as the Company’s interim Chief Financial Officer since April 15, 2022, will continue as the Company’s EVP, Administration.
On March 27, 2023, the Board of Directors (the “ Board ”) of MaxCyte, Inc. (the “ Company ”) appointed Douglas J. Swirsky as the Company’s Chief Financial Officer, effective immediately.
On November 30, 2022, upon the recommendation of its Nominating and Corporate Governance Committee (the “ Nominating Committee ”), the Board of Directors (the “ Board ”) of MaxCyte, Inc. (the “ Company ”) appointed Patrick J. Balthrop, Sr. to serve as a Class II director.
On April 8, 2022, the Board of Directors of the Company appointed Ron Holtz, currently the Company’s Senior Vice President and Chief Accounting Officer, as Interim Chief Financial Officer, effective upon Ms. Murphy’s departure.
On April 7, 2022, Amanda L. Murphy, Chief Financial Officer of the Company, resigned from that position, effective as of April 15, 2022, to pursue other interests.
On September 30, 2021, Dr. J. Stark Thompson notified the board of directors (the “ Board ”) of MaxCyte, Inc. (the “ Company ”) that he will not stand for re-election at the Annual Meeting of Stockholders to be held on October 29, 2021 (the “ Annual Meeting ”).
Max materiality 0.85 · Median 0.65 · Most common event earnings